tbuckley/cabot-search huggingface dataset:
OP0217 Ultrasound-Detected Synovitis and Tenosynovitis Independently Associate with Flare in Patients with Rheumatoid Arthritis in Clinical Remission
Authors: E. Bellis, C.A. Scirè, G. Carrara, A. Adinolfi, A. Batticciotto, A. Bortoluzzi, G. Cagnotto, M. Caprioli, M. Canzoni, F.P. Cavatorta, O. De Lucia, V. Di Sabatino, A. Draghessi, G. Filippou, I. Farina, M.C. Focherini, A. Gabba, M. Gutierrez, L. Idolazzi, F. Luccioli, P. Macchioni, M.S. Massarotti, C. Mastaglio, L. Menza, M. Muratore, S. Parisi, V. Picerno, M. Piga, R. Ramonda, B. Raffeiner, D. Rossi, S. Rossi, P. Rossini, G. Sakellariou, C. Scioscia, C. Venditti, A. Volpe, M. Matucci-Cerinic, A. Iagnocco
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Remission is the target of treatment in rheumatoid arthritis (RA). In clinically-defined remission, subclinical disease activity may persist leading to flare and joint damage progression. Musculoskeletal ultrasonography (MSUS) is a good candidate to overcome the limitations of clinimetric indexes. The role of MSUS synovitis is well-known in the literature but no data are available for tenosynovitis. <h3>Objectives</h3> The study aims to evaluate the association between US synovitis (S) and tenosynovitis (T) and 6-month flare in RA patients in clinical remission. <h3>Methods</h3> The STARTER study is a multicentre cohort study promoted by the Italian Society for Rheumatology. Ultrasonographers were selected by an inter-reader reliability exercise. Consecutive patients with RA and clinical remission underwent a full clinical evaluation and Grey Scale (GS) and power Doppler (PD) US exam (assessing -S and -T) at wrists, MCP, PIP and extensor/flexor tendon sheets. Six-month flare was defined as: 1) increase of &gt;1.2 or &gt;0.6 if final DAS28&gt;3.2; 2) change in treatment; 3) change of &gt;4 points in the flare questionnaire (FQ) if FQ&lt;4 at baseline. The relationships between presence of GS-T/-S, PD-T/-S were evaluated by logistic models, presented as odds ratios (OR) and 95%CI, adjusted for pre-specified confounders. <h3>Results</h3> A total of 427 patients were included in the analyses: 113 (26.5%) men, mean (SD) age 56.6 (13.4), median (IQR) disease duration 7.3 (3.8-13.5) years, median (IQR) remission duration 12 (8-24) months, RF positive 287 (67.4%), mean (SD) DAS28 2.2 (0.8), median (IQR) HAQ 0.125 (0-0.375), on DMARDs 322 (75.4%), on biologics 183 (42.9%), on glucocorticoids 187 (43.8%). GS-T was present in 198/373 (53.1%) patients, PD-T in 88/372 (23.7%) while GS-S in 270/368 (73.4%) and PD-S in 171/372 (46.5%). The association between US variables and flare is reported in the Table. <h3>Conclusions</h3> MSUS PD-S confirms its predictivity on flare defined according to DAS28 definitions while PD-T is more specifically associated with patient-related flare and symptoms exacerbation. US-T should be take into account in the management of RA patients in clinical remission. <h3>Disclosure of Interest</h3> None declared
Length of stay and recidivism in schizophrenia: a study of public psychiatric hospital patients
Authors: L Appleby, P N Desai, D J Luchins, R D Gibbons, D R Hedeker
Journal: American Journal of Psychiatry (1993)

Psychiatric beds in public hospitals have decreased 80% since 1955, but admissions have risen correspondingly, largely because of high recidivism rates. Decreases in numbers of beds have been partly achieved by shortening the length of stay, which lessened by half between 1970 and 1980. This study was undertaken to determine whether duration of hospital treatment affects the rate and rapidity of relapse among schizophrenic patients.Data on 1,500 patients from 10 state hospitals were gathered for 18 months after initial discharge. Predictor variables included age, sex, marital status, race, number of previous admissions, location of the facility, and length of stay. Data were analyzed by survival analysis with a Cox regression model for two times to initial relapse: 30 days and 18 months (outcome).Length of stay was significantly related to each time to relapse after the effects of number of previous admissions and age were partialed out. Facility location was not predictive, but intrahospital effects were tested by examining the data on the largest facility; again, length of stay significantly predicted relapse.Although the magnitude of the effect was small, the clinical significance of the findings is the greater likelihood that brief-stay patients will be rehospitalized within 30 days after discharge than will patients treated for longer periods. Brief hospitalization seems generally applicable to psychiatric populations, but there may be a small but important group of seriously mentally ill patients for whom other alternatives are possibly more appropriate and should be explored.
FRI0031 Relationship Between Ultrasonographic Synovitis Score, MMP-3 and Calprotectin Serum Levels in Patients with Rheumatoid Arthritis During Etanercept Therapy
Authors: A. Pchelintseva, M. Severinova, A. Zhornyak, N. Ionichenok, E. Panasyuk, M. Cherkasova, A. Volkov, L. Denisov
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Etanercept (ETN) is effective anti-TNF treatment for rheumatoid arthritis (RA). Calprotectin (CP) and Matrix metalloproteinase-3 (MMP-3) are biomarkers associated with disease activity and joint destruction in RA. Ultrasonography (US) is a reliable method for detection and evaluation of synovitis. <h3>Objectives</h3> To explore associations between CP, MMP-3 serum levels and US synovitis score (B-mode -BM and power Doppler-PD) in RA patients during ETN therapy. <h3>Methods</h3> 26 subjects aging ≥18 years with moderate-to-severe RA despite stable doses of conventional DMARDs (DAS28 6,22±0,91) had received ETN 50 mg weekly subcutaneously for 24 weeks. The mean age was 50,8±13,5 years, mean RA duration 6,9±6,1 years, 88% were women, 65% were RF+. Routine clinical and laboratory evaluation was done at weeks 0 and 25. US examination was performed before start of ETN treatment and after 6 month of ETN therapy by the same independent sonographer. 7-joint score (grade 0-3) included wrist, intercarpal, 2-3 MCP, 2-3 PIP joints of the clinically dominant hand and knee was used. CP and MMP-3 serum levels (ELISA) were measured at the same time points. Associations between US sum scores, CP, MMP-3, CRP, ESR and DAS28 were evaluated. <h3>Results</h3> All clinical, laboratory and US parameters of RA activity had significantly improved during ETN therapy (table 1) We did not determine any associations between Me Δ CP and MMP-3 with Me Δ of US synovitis score (both BM and PD). We explored the significant correlation between baseline CP, MMP-3 serum levels and BM sum score at week 25 (r=0,61 and 0,44 respectively) (Fig.1) Despite achievement remission/low disease activity according EULAR subclinical synovitis was detected in the most patients (n=24, 92%) at week 25. <h3>Conclusions</h3> US sum score decreased significantly in parallel with CP and MMP-3 serum levels during ETN therapy. There was not any correlation of MeΔ CP and MMP-3 with MeΔ US sum score. CP and MMP-3 baseline concentrations strongly correlated with B-mode score at week 25. High baseline CP and MMP-3 levels may be predictive factors of poor response to ETN treatment. Our findings support that CP and MMP-3 are useful biomarkers for monitoring of synovitis in RA during anti-TNF therapy. US response is delayed in comparison with clinical effect and decrease in CP and MMP-3 concentrations. <h3>References</h3> Hammer HB, Fagerhol MK, Wien TN, Kvien TK. The soluble biomarker calprotectin (an S100 protein) is associated to ultrasonographic synovitis scores and is sensitive to change in patients with rheumatoid arthritis treated with adalimumab. Arthritis Res Ther. 2011;13(5):R178. <h3>Disclosure of Interest</h3> None declared
Pertussis outbreak detected by active surveillance in Cyprus in 2003
Authors: M Theodoridou, A Hadjipanagis, N Persianis, S Makri, C Hadjichristodoulou
Journal: Eurosurveillance (2007)

Pertussis is a disease of substantial public health importance that still lacks an efficient surveillance system. It has been a notifiable disease in Cyprus since 1930, and has had an incidence rate of 1 per 100,000 persons during the last 10 years. In 2001, the Greece-Cyprus Paediatric Surveillance Unit (GCPSU) was established with the aim of active surveillance for rare paediatric diseases, including weekly data reporting, zero reporting, and obligatory laboratory tests. From November 2002, pertussis has been included in the active surveillance scheme of GCPSU, resulting in a very early detection of an outbreak in June 2003 that led to immediate and successful action.
Aerosol Sprays
Authors: M. R. Zavon
Journal: JAMA (1975)

<h3>To the Editor.—</h3> A recent Questions and Answers section (231:1289, 1975) had a nicely balanced and very fair answer to the question of hazard from aerosol hair sprays and antiperspirants. However, though very fair and evenly balanced, I would think that it would leave your questioner almost exactly where he started. Dr. Jerome states "the present state of knowledge gives aerosol products, in normal use, a clean bill of health." At the same time, Mr. Wheater states "it must be concluded that all aerosol consumer products are potentially dangerous to humans." Both answers are correct and not as contradictory as may appear at first glance. The phrase "present state of knowledge" limits us to what we now know, which is the only legitimate basis for decision-making in the here and now. The phrase "potentially dangerous to humans" could be extended to all products. Mr. Wheater's reply lumps together a series
Deoxyribonucleic Acid Content of HeLa Stock and Newly Established Clone Cultures
Authors: Milton N. Goldstein, John Gallagher
Journal: JNCI Journal of the National Cancer Institute (1959)

The deoxyribonucleic acid (DNA) content was determined in individual cells of Feulgen-stained HeLa stock and newly established HeLa clones with a redesigned sensitive cytophotometer. The DNA content varied in cells of the stock. Similar variations in DNA were observed in clones by the time 10 divisions had occurred. Morphologic observations and cytophotometric measurements indicated that the DNA in the particular HeLa cells studied and grown under the conditions described did not reduplicate in a uniformly stable manner in populations which were started from single cells.
Interrelations in Respiratory, Phos-phorylative, and Mitotic Activity of Ehrlich Ascites-Tumor Cells: Influence of Stilbestrol and Quinone
Authors: B SHACTER
Journal: JNCI Journal of the National Cancer Institute (1956)

Journal Article Interrelations in Respiratory, Phos-phorylative, and Mitotic Activity of Ehrlich Ascites-Tumor Cells: Influence of Stilbestrol and Quinone Get access Bernard Shacter Bernard Shacter Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 16, Issue 6, June 1956, Pages 1453–1458, https://doi.org/10.1093/jnci/16.6.1453 Published: 01 June 1956
FRI0298 Differences Between Clinical and Densitometric Risk Factors in Patients with and Without Fragility Fractures in a Bone Metabolism Unit (BMU):
Authors: J.J. Aznar, S.M. Rojas, L.M. Mellado, P.J. Cossío, T.L. Rodriguez Araya, R. Veroz, A.M. Gallego, E. Chamizo
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Identification of fracture risk factors, Bone Mineral Densitometry (BMD) and FRAX application have helped to decrease the variability of the diagnosis and treatment in patients with osteoporosis (OP). More investigation is needed to identify the differences between patients that are susceptible to fractures. <h3>Objectives</h3> Identify the differences in BMD and fracture risk factors (FRAX) between patients with and without fragility fractures. <h3>Methods</h3> Patients attended a high resolution consultation of OP in the BMU of the Rheumatology Unit in the Hospital of Mérida, from July 2013 to June 2014, collecting information about fracture risk factors, lumbar-BMD (L2-L4) and hip-BMD, radiology of dorsolumbar spine and vitamin D. FRAX with and without BMD was calculated in all patients. <h3>Results</h3> We studied 355 patients who had all the information needed. 81 patients presented clinical or morphometric fractures, with a mean age of 69.28±2,88 years, slightly higher than the 274 patients without fractures (62.61±1.31). The differences in the rates of densitometric OP between fractured and non-fractured patients were 23.4% and 21.1% in lumbar spine and 18.5% and 10.9% in hip with an OR 1.85 (0.94-3.64) and Ji<sup>2</sup> 3.24 (p=0.07). The rate of fractured patients with Major osteoporotic fracture &gt;10% and hip fracture &gt;3% in FRAX were 12.34% and 22.22%. When DMO is added to the calculation the rates increased to 16.04% and 23.45%, respectively. In non-fractured patients, the rate of major fracture of 20.43% and hip fracture of 25.18% decreased when DMO was added to the calculation of FRAX to 14.96% and 21.89%, respectively. The rate of patients with levels of vitamin D&lt;20ng/ml was 19.75% in fractured patients and 16.05% in non-fractured patients. <h3>Conclusions</h3> The Mean age in fractured patients was higher than in non-fractured patients, in accordance to other studies in the literature that age is an important risk factor for fractures. The rate of desitometric OP in patients with or without fractures was similar in lumbar spine, but we find higher rate of hip OP in fractured patients although without statistical differences. In our study, the calculation of FRAX without BMD underestimates the fracture risk in fractured patients respect to the non-fractured patients. However, when the BDM is added to the calculation of FRAX, this evaluation of the fracture risk in fractured patients improves. We didn9t find any statistically difference between rates of patients with levels of vitamin D&lt;20ng/ml and &gt;20ng/ml. <h3>Disclosure of Interest</h3> None declared
Electroconvulsive therapy
Authors: S. Carney
Journal: BMJ (2003)

<h3>Objectives</h3> To illustrate the importance of preoperative MRI in the surgical treatment decision in patients with invasive breast cancer. <h3>Methods</h3> We reviewed retrospectively the preoperative MRI (3 Tesla) of 169 patients operated at Hôtel-Dieu de France for invasive breast cancer. The sequences of 85 patients who underwent a radical treatment (mastectomy) were compared to those of 84 patients who benefited from conservative surgery. We estimated the tumor volume (TV) and breast volume (BV) on enhanced MRI and then we compared the tumor volume to breast volume ratio (TV/BV) in both groups. <h3>Results</h3> We reviewed retrospectively the preoperative MRI (3 Tesla) of 169 patients operated at Hôtel-Dieu de France for invasive breast cancer. The sequences of 85 patients who underwent a radicaltreatment (mastectomy) were compared to those of 84 patients who benefited from conservative surgery.We estimated the tumor volume (TV) and breast volume (BV) on enhanced MRI and then we comparedthe tumor volume to breast volume ratio (TV/BV) in both groups. <h3>Conclusions</h3> Our data suggest that preoperative MRI can aid the surgical treatment decision in patients with invasive breast cancer by assessing the tumor to breast volume ratio as well as by providing a full mapping of multifocal and multicentric lesions in the breast tissue.
A retrospective cohort study of patients with pulmonary embolism: the impact of comorbidities on patient's outcome
Authors: Antonella Mameli, Maria Antonietta Palmas, Antonello Antonelli, Paolo Contu, Paolo Prandoni, Francesco Marongiu
Journal: European Respiratory Journal (2016)

Despite considerable advances in diagnosis and treatment, pulmonary embolism (PE) remains is an important clinical entity with a high risk of death. Due to pulmonary bed obstruction, PE can result in acute right ventricular failure, a life-threatening condition. Possible protective effect against mortality from pulmonary embolism may relate to concomitant DVT and hypertension <http://ow.ly/4nfs7v>
Infectious Complications In 96 Matched-Related Bone Marrow Transplants Performed Without Positive Pressure Room Or Centralized Hepa Filtration In Lower Middle Income Countries
Authors: Mohamed El Missiry, Sadaf Khaled, Naila Yaqub, Priya Marwa, Rajpreet Soni, Saqib Ansar, Yasir Iqbal, Uderzo Cornelio, Lawrence B. Faulkner
Journal: Blood (2013)
Reply to Barresi et al.
Authors: Mohammad Al-Haddad, Thomas Kowalski
Journal: Endoscopy (2015)

We thank Dr. Barresi and his colleagues for their interest in our work. Between-study comparisons of performance characteristics are valid only when the clinical end points and patient populations examined are comparable. These features differed significantly between our study [1] and the study of Goh et al. [2], accounting for the difference in positive predictive values (PPVs).
Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
Authors: Sandra Ortiz-Cuaran, Matthias Scheffler, Dennis Plenker, llona Dahmen, Andreas H. Scheel, Lynnette Fernandez-Cuesta, Lydia Meder, Christine M. Lovly, Thorsten Persigehl, Sabine Merkelbach-Bruse, Marc Bos, Sebastian Michels, Rieke Fischer, Kerstin Albus, Katharina König, Hans-Ulrich Schildhaus, Jana Fassunke, Michaela A. Ihle, Helen Pasternack, Carina Heydt, Christian Becker, Janine Altmüller, Hongbin Ji, Christian Müller, Alexandra Florin, Johannes M. Heuckmann, Peter Nuernberg, Sascha Ansén, Lukas C. Heukamp, Johannes Berg, William Pao, Martin Peifer, Reinhard Buettner, Jürgen Wolf, Roman K. Thomas, Martin L. Sos
Journal: Clinical Cancer Research (2016)

To identify novel mechanisms of resistance to third-generation EGFR inhibitors in patients with lung adenocarcinoma that progressed under therapy with either AZD9291 or rociletinib (CO-1686).
PTH-039 Longitudinal follow-up for pancreatobiliary malignancy in patients who underwent an endoscopic ultrasound
Authors: W On, Y Lim, O Patani, N Kapoor
Journal: Gut (2015)

<h3>Introduction</h3> Endoscopic ultrasound (EUS) is commonly used in the investigation of patients for pancreatobiliary disorders in the setting of a dilated common bile duct (CBD) and/or abnormal liver function tests (LFTs). There is scant literature about the natural history of such patients who undergo an EUS and their future outcomes. We aimed to perform a longitudinal follow-up of these patients with special regards to the development of pancreatobiliary malignancy. <h3>Method</h3> 173 patients (54 males and 119 females) with a median age of 60 (IQR 46–71) who underwent an EUS at our hospital in 2010 were identified. Patients who were referred from another hospital for an EUS were excluded as they were followed up elsewhere. Details of all endoscopic procedures were obtained from our endoscopy reporting tool. Follow-up data were retrieved from our hospital’s electronic records which included blood tests, radiology reports and clinic letters. <h3>Results</h3> The initial EUS diagnoses were: Normal (n = 100, 57.8%), gallstone disease (n = 63, 36.4%), pancreatic cancer (n = 5, 2.9%), cholangiocarcinoma (n = 1, 0.6%), intraductal papillary mucinous neoplasm (n = 1, 0.6%), gall bladder cancer (n = 1, 0.6%) and chronic pancreatitis (n = 2, 1.2%). The median follow-up time was 51 months (IQR 48–54). 1 patient was diagnosed with metastatic pancreatic adenocarcinoma after presenting with worsening abdominal pain and weight loss at 10 months from initial EUS which had showed a diagnosis of gallstone disease. No other pancreatobiliary malignancies were diagnosed in any other patients during the follow-up period aside from those already diagnosed at the time of the original EUS. <h3>Conclusion</h3> A non-malignant diagnosis at EUS does not exclude the possibility of a malignant pancreatobiliary disease in the future. A low threshold for reinvestigating is mandated especially if there are suspicious signs and symptoms. <h3>Disclosure of interest</h3> None Declared.
A Woman with Dyspnea and Altered Mental Status
Authors: Kunal P. Patel, Anand Vaidya, Christopher J. Gibson, Timothy J. Henrich, Jennifer L. Lyons
Journal: New England Journal of Medicine (2016)

A 59-year-old black woman with systemic lupus erythematosus (SLE) presented to the emergency department with new-onset lethargy and shortness of breath. She had received a diagnosis of SLE 15 years earlier, after presenting with joint pain and swelling, and was treated with azathioprine. The disease had been in remission until 3 months before the current presentation . . .
PWE-203 Endoscopic transgastric pancreatic necrosectomy (ETN) – a safe and effective treatment for infected pancreatic necrosis
Authors: T Duncan, R Bamford, S Griffiths, A Strickland
Journal: Gut (2015)

<h3>Introduction</h3> Infected pancreatic necrosis remains associated with high morbidity and mortality rates. Historically open necrosectomy operative mortality reached 50%. Minimally invasive techniques have been demonstrated to decrease morbidity but not mortality compared to open surgery as highlighted in the PANTER trial. We present our own series of patient results treated with this innovative procedure. <h3>Method</h3> All patients managed with ETN at our HPB unit were identified. Patient demographics, diagnosis, primary and secondary outcomes were recorded. Primary outcomes included 30 and 90 day mortality, major morbidity ie: new onset organ failure, haemorrhage or perforation. Secondary outcomes included length of stay in hospital, ITU stay, number of procedures, other interventions required and endocrine/exocrine insufficiency. <h3>Results</h3> 12 patients were treated with ETN, 8 males, 4 females with an age range of 21–81. All patients underwent endoscopic ultrasound guided cyst-gastroscopy with stent insertion as initial therapy. A median of two (1–6) endoscopic pancreatic necrosectomies were required with a median of three (1–4) admissions. Average length of stay per admission was 10 days (1–65). One patient was treated with a percutaneous drain initially and then went on to endoscopic treatment and early removal of drain. 25% of patients (3/12) required intensive care admission. No perforations, haemorrhage, 30 or 90 days deaths were recorded. <h3>Conclusion</h3> Endoscopic, transgastric pancreatic necrosectomy appears a safe and effective procedure for the management of this patient group. Our results compare favourably with those following open necrosectomy and are similar to published minimally invasive technique outcomes. <h3>Disclosure of interest</h3> None Declared. <h3>References</h3> Van Santvoort, Besselink MG, <i>et al</i>. A step up approach or open necrosectomy for necrotising pancreatitis. <i>N Eng J Med.</i>2010 Apr 22;362(16):1491–502. Kokosis G. Surgical managemnt of necrotising pancreatitis an overview. <i>Worls J of Gastroenterol</i>. 2014 Nov 21;20/43:16106–16112 Charnley RM. Endoscopic necrosectomy as primary therapy in management of infected pancreatic necrosis. Endoscopy 2006;38:925–928. Baron TH. Endoscopic therapy for organised pancreatic necrosis. Gastroenterology 1996;755–61. Branum G. Pancreatic necrosis results of necrosectomy packing and ultimate closure over drains. Ann Surg. 1998;227(6):870–877.